
PNH Treatment: A New Era - Advances in Paroxysmal Nocturnal Hemoglobinuria
Newer drugs for paroxysmal nocturnal hemoglobinuria (PNH) are revolutionizing the field, improving quality of life and reducing fatigue.1
PNH, a rare condition, is characterized by chronic destruction of red blood cells (hemolysis), resulting in anemia and fatigue, which can significantly affect patients’ quality of life. The chronic nature of the disease, with different treatment requirements, also contributes negatively to quality of life. Increased risk of complications, including breakthrou
PNH, a rare condition, is characterized by chronic destruction of red blood cells (hemolysis), resulting in anemia and fatigue, which can significantly affect patients’ quality of life. The chronic nature of the disease, with different treatment requirements, also contributes negatively to quality of life. Increased risk of complications, including breakthrou